Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...

The narcolepsy treatment market is projected to grow from USD 5,301.6 million in 2024 to USD 8,718.3 million by 2034, at a ...

Harmony Biosciences Holdings, Inc. today announced strong preliminary, unaudited net product revenues for Q4 and full year 2024 of $201 million and $714 million, respectively. Building on this ...

Auvelity preliminary 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectivelySunosi preliminary 4Q and full year ...

Awareness of sleep apnea and its relatively common and effective treatment has grown over the past three decades.

The FDA has expanded the approval of Lumryz (sodium oxybate) extended-release oral suspension to include treatment of pediatric narcolepsy.

Copay Assistance From The Assistance Fund Now Available for Eligible People Living With Narcolepsy. ORLANDO, FLORIDA / ACCESSWIRE / January 9, 2025 / The Assistance Fund, an indep ...

Avadel said it expects Lumryz to generate about $50 million in revenue for the fourth quarter, missing current analyst forecasts by $3.7 million, and $169 million for the full year, $1.7 million shy ...

Avadel Pharmaceuticals expects its narcolepsy treatment Lumryz to drive strong revenue growth in the fourth quarter and into 2025, preliminary earnings show.

About LUMRYZ™ (sodium oxybate) for extended-release oral suspension LUMRYZ, is an extended-release sodium oxybate medication approved by the FDA on May 1, 2023, as the first and only once-at-bedtime ...

Combining Adderall with other CNS stimulants, such as caffeine, can increase the risk of side effects, including elevated ...

Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces today that it has acquired at the end ...